SMARCB1-Retained and SMARCB1-Deficient SNUC are Genetically Distinct: A Pilot Study Using RNA Sequencing

Abstract

Background Understanding the genetic basis for the molecular classification of sinonasal undifferentiated carcinoma (SNUC) based on SMARCB1 may improve our understating regarding the nature of the disease. The objective of the study was to compare the genetic profile of SMARCB1-retained (SR-SNUC) and SMARCB1-deficient SNUC (SD-SNUC).

Methods Formalin-fixed, paraffin-embedded tissue from treatment-naive patients with SNUC were selected. Three cases of SR-SNUC, four cases of SD-SNUC, and four samples of nontumor tissue (control samples) were selected. Ribonucleic acid (RNA) sequencing was performed.

Results SR-SNUC had a higher number of variants (1 variant for every 15,000 bases) compared with SD-SNUC (1 variant every 29,000 bases). The ratio of missense to silent mutation ratio was higher for SR-SNUC (0.8) as compared with SD-SNUC (0.7). Approximately 1,500 genes were differentially expressed between SR-SNUC and SD-SNUC. The genes that had a higher expression in SR-SNUC included TPD52L1, B3GNT3, GFY, TJP3, ELL3, CYP4F3, ALDH3B2, CKMT1B, VIPR1, SLC7A5, PPP2R2C, UPK3B, MUC1, ELF5, STY7, and H2AC14. The gene that had a higher expression in SD-SNUC was ZFHX4. Most of these genes were related to either protein translation or immune regulation. The most common (n = 3, 75%) mechanisms of loss of SMARCB1 gene in SD-SNUC was loss of heterozygosity.

Conclusion RNA sequencing is a viable and informative approach for genomic profiling of archival SNUC samples. Both SR-SNUC and SD-SNUC were noted to have distinct genetic profiles underlying the molecular classification of these diseases.

Keywords

SMARCB1 - SNUC - RNA sequencing - INI-1 - sinonasal cancer

Presentation

Oral presentation at North American Skull base society (NASBS) annual meeting at Phoenix, Arizona on February 18–20, 2022.

Publication History

Received: 28 January 2023

Accepted: 03 May 2023

Accepted Manuscript online:
08 May 2023

Article published online:
12 June 2023

• References

• 1 El-Naggar AK, Chan JKC, Grandis JR, Takata T, Slootweg PJ. eds. WHO Classification of Head and Neck Tumours. 4th ed.. Lyon, France: IARC; 2017
• 2 Musy PY, Reibel JF, Levine PA. Sinonasal undifferentiated carcinoma: the search for a better outcome. Laryngoscope 2002; 112 (8 Pt 1): 1450-1455
• 3 Rischin D, Porceddu S, Peters L, Martin J, Corry J, Weih L. Promising results with chemoradiation in patients with sinonasal undifferentiated carcinoma. Head Neck 2004; 26 (05) 435-441
• 4 Lin EM, Sparano A, Spalding A. et al. Sinonasal undifferentiated carcinoma: a 13-year experience at a single institution. Skull Base 2010; 20 (02) 61-67
• 5 Xu CC, Dziegielewski PT, McGaw WT, Seikaly H. Sinonasal undifferentiated carcinoma (SNUC): the Alberta experience and literature review. J Otolaryngol Head Neck Surg 2013; 42 (01) 2
• 6 Khan MN, Konuthula N, Parasher A. et al. Treatment modalities in sinonasal undifferentiated carcinoma: an analysis from the national cancer database. Int Forum Allergy Rhinol 2017; 7 (02) 205-210
• 7 Chitguppi C, Rabinowitz MR, Johnson J. et al. Loss of SMARCB1 expression confers poor prognosis to sinonasal undifferentiated carcinoma. J Neurol Surg B Skull Base 2020; 81 (06) 610-619
• 8 Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics 2011; 12: 323
• 9 Dobin A, Davis CA, Schlesinger F. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 2013; 29 (01) 15-21
• 10 Okonechnikov K, Conesa A, García-Alcalde F. Qualimap 2: advanced multi-sample quality control for high-throughput sequencing data. Bioinformatics 2016; 32 (02) 292-294
• 11 Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 2014; 15 (12) 550
• 12 Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B (Methodological) 1995; 57 (01) 289-300
• 13 Takahashi Y, Gleber-Netto FO, Bell D. et al. Identification of novel diagnostic markers for sinonasal undifferentiated carcinoma. Head Neck 2019; 41 (08) 2688-2695
• 14 Heft Neal ME, Birkeland AC, Bhangale AD. et al. Genetic analysis of sinonasal undifferentiated carcinoma discovers recurrent SWI/SNF alterations and a novel PGAP3-SRPK1 fusion gene. BMC Cancer 2021; 21 (01) 636
• 15 Kakkar A, Rathor A, Ashraf SF, Singh V, Sikka K, Jain D. IDH1/2 mutations in sinonasal undifferentiated carcinomas : previously undescribed IDH2 R172K and R140x variants. Am J Surg Pathol 2022; 46 (09) 1284-1290
• 16 Del Savio E, Maestro R. Beyond SMARCB1 loss: recent insights into the pathobiology of epithelioid sarcoma. Cells 2022; 11 (17) 2626
• 17 Kalimuthu SN, Chetty R. Gene of the month: SMARCB1. J Clin Pathol 2016; 69 (06) 484-489
• 18 Geller JI, Roth JJ, Biegel JA. Biology and treatment of rhabdoid tumor. Crit Rev Oncog 2015; 20 (3-4): 199-216
• 19 Thompson LDR, Bishop JA. Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: nasal cavity, paranasal sinuses and skull base. Head Neck Pathol 2022; 16 (01) 1-18
• 20 Agaimy A, Koch M, Lell M. et al. SMARCB1(INI1)-deficient sinonasal basaloid carcinoma: a novel member of the expanding family of SMARCB1-deficient neoplasms. Am J Surg Pathol 2014; 38 (09) 1274-1281
• 21 Agaimy A, Hartmann A, Antonescu CR. et al. SMARCB1 (INI-1)-deficient sinonasal carcinoma: a series of 39 cases expanding the morphologic and clinicopathologic spectrum of a recently described entity. Am J Surg Pathol 2017; 41 (04) 458-471
• 22 El-Naggar AK, Chan JKC, Grandis JR, Takata T, Slootweg PJ. WHO Classification of Head and Neck Tumours. 4th eds.. Lyon, France: International Agency for Research on Cancer; 2017
• 23 Lee VH, Tsang RK, Lo AWI. et al. SMARCB1 (INI-1)-deficient sinonasal carcinoma: a systematic review and pooled analysis of treatment outcomes. Cancers (Basel) 2022; 14 (13) 3285
• 24 Qing T, Zhu S, Suo C, Zhang L, Zheng Y, Shi L. Somatic mutations in ZFHX4 gene are associated with poor overall survival of Chinese esophageal squamous cell carcinoma patients. Sci Rep 2017; 7 (01) 4951
• 25 Zong S, Xu PP, Xu YH, Guo Y. A bioinformatics analysis: ZFHX4 is associated with metastasis and poor survival in ovarian cancer. J Ovarian Res 2022; 15 (01) 90
• 26 Fu Y, Liu S, Rodrigues RM. et al. Activation of VIPR1 suppresses hepatocellular carcinoma progression by regulating arginine and pyrimidine metabolism. Int J Biol Sci 2022; 18 (11) 4341-4356
• 27 Bell D, Hanna EY, Weber RS. et al. Neuroendocrine neoplasms of the sinonasal region. Head Neck 2016; 38 (Suppl. 01) E2259-E2266
• 28 Mills SE, Fechner RE. “Undifferentiated” neoplasms of the sinonasal region: differential diagnosis based on clinical, light microscopic, immunohistochemical, and ultrastructural features. Semin Diagn Pathol 1989; 6 (04) 316-328
• 29 Labani-Motlagh A, Ashja-Mahdavi M, Loskog A. The tumor microenvironment: a milieu hindering and obstructing antitumor immune responses. Front Immunol 2020; 11: 940
• 30 Yoshihara K, Shahmoradgoli M, Martínez E. et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun 2013; 4: 2612